December 17th, 2024
Hansoh Pharma (03692.HK) announces that, HS-20110 for injection, which is a new antibody-drug conjugate (ADC) independently developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China on December 16, 2024, which is intended to be investigated in clinical trials for advanced solid tumors.
